These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11763420)

  • 1. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
    Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR
    J Neurooncol; 2001 Aug; 54(1):31-8. PubMed ID: 11763420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
    Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
    J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
    J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
    Puduvalli VK; Giglio P; Groves MD; Hess KR; Gilbert MR; Mahankali S; Jackson EF; Levin VA; Conrad CA; Hsu SH; Colman H; de Groot JF; Ritterhouse MG; Ictech SE; Yung WK
    Neuro Oncol; 2008 Apr; 10(2):216-22. PubMed ID: 18314417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.
    Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G
    Oncol Rep; 2004 Jan; 11(1):93-5. PubMed ID: 14654909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
    J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
    Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
    Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
    Chang SM; Wen P; Cloughesy T; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; De Angelis L; Raizer J; Hess K; Aldape K; Lamborn KR; Kuhn J; Dancey J; Prados MD;
    Invest New Drugs; 2005 Aug; 23(4):357-61. PubMed ID: 16012795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme.
    Oudard S; Carpentier A; Banu E; Fauchon F; Celerier D; Poupon MF; Dutrillaux B; Andrieu JM; Delattre JY
    J Neurooncol; 2003 May; 63(1):81-6. PubMed ID: 12814259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
    Fadul CE; Kingman LS; Meyer LP; Cole BF; Eskey CJ; Rhodes CH; Roberts DW; Newton HB; Pipas JM
    J Neurooncol; 2008 Nov; 90(2):229-35. PubMed ID: 18661102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
    Schiff D; Jaeckle KA; Anderson SK; Galanis E; Giannini C; Buckner JC; Stella P; Flynn PJ; Erickson BJ; Schwerkoske JF; Kaluza V; Twohy E; Dancey J; Wright J; Sarkaria JN
    Cancer; 2018 Apr; 124(7):1455-1463. PubMed ID: 29313954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma.
    Phuphanich S; Scott C; Fischbach AJ; Langer C; Yung WK
    J Neurooncol; 1997 Sep; 34(2):193-200. PubMed ID: 9210068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study.
    Gwak HS; Youn SM; Kwon AH; Lee SH; Kim JH; Rhee CH
    J Neurooncol; 2005 Nov; 75(2):173-80. PubMed ID: 16132508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
    Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
    Giglio P; Dhamne M; Hess KR; Gilbert MR; Groves MD; Levin VA; Kang SL; Ictech SE; Liu V; Colman H; Conrad CA; Loghin M; de Groot J; Yung WK; Puduvalli VK
    Cancer; 2012 Jul; 118(14):3599-606. PubMed ID: 22086614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
    Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
    Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
    J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.